Taking place 7 June, the Medicines Manufacturing Industry Partnership Annual Conference will be hosted by GlaxoSmithKline (GSK) at its UK site in Stevenage.
The conference - Propelling growth: taking the next step in innovative medicines manufacturing - will bring together global companies to showcase the successes and future innovation of this emerging sector – already one of the UK’s leading manufacturing sectors, worth £30 bn to the economy.
Delegates will hear from companies including GSK, AstraZeneca, Siemens and Benevolent AI on how future developments in artificial intelligence, synthetic biology and digital manufacturing are all playing a role in innovation in manufacturing.
Opened only one month ago, the Cell and Gene Therapy manufacturing centre based at GSK’s Stevenage site will be available for guests to see its high-tech facilities.
The Government-funded plant is designed to support the global gene therapy industry and is an important step in ensuring that the UK is perfectly placed to play a leading role in advanced manufacturing.
Andy Evans, AstraZeneca and Chair of MMIP said: “The UK already plays a leading role in the research and development of the medicines globally. As the advanced therapy manufacturing market continues to grow significantly, it’s the right time for the UK to show it can emerge as a global player in this area.”
“With Government and Industry continuing to back the sector financially and with world-leading facilities we are set to see cutting edge, advanced manufacturing innovation capability – including those showcased at this year’s MMIP Conference - added to the UK’s already impressive academic and research and development eco-system.”
Speakers at the conference include manufacturing experts from across Government, industry and the private sector, including GSK, AstraZeneca, Innovate UK, Benevolent AI, Siemens, SBLC and OxfordBiomedica.